OLX703A

**OLX703A** is an investigational **GalNAc-conjugated asymmetric small interfering RNA** therapeutic from **OliX Pharmaceuticals** being developed for **chronic hepatitis B virus infection**. It is designed to target a sequence conserved across all major HBV transcripts, enabling broad knockdown of viral RNA and suppression of HBV proteins including **hepatitis B surface antigen** as well as other virologic markers such as e-antigen and HBV DNA. The program uses OliX's **GalNAc-asiRNA** platform to support hepatocyte-directed delivery, and preclinical reports indicate activity across major HBV genotypes and subtypes, with the asset remaining in preclinical or early development based on the provided information.